Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04419506




Registration number
NCT04419506
Ethics application status
Date submitted
4/06/2020
Date registered
5/06/2020
Date last updated
1/11/2022

Titles & IDs
Public title
A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Scientific title
A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally
Secondary ID [1] 0 0
2019-004167-45
Secondary ID [2] 0 0
1305-0013
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BI 1015550
Treatment: Drugs - Placebo

Placebo Comparator: Placebo, Antifibrotics at baseline - Idiopathic pulmonary fibrosis (IPF) patients on stable antifibrotic treatment with nintedanib or pirfenidone at baseline were administered placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks. During the 12-weeks of administration of BI 1015550 patients stayed on their stable background therapy of nintedanib or prifenidone.

Experimental: BI 1015550, Antifibrotics at baseline - Idiopathic pulmonary fibrosis (IPF) patients on stable antifibrotic treatment with nintedanib or pirfenidone at baseline were administered 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks. During the 12-weeks of administration of BI 1015550 patients stayed on their stable background therapy of nintedanib or prifenidone.

Placebo Comparator: Placebo, Non-antifibrotics at baseline - Idiopathic pulmonary fibrosis (IPF) patients not on stable antifibrotic treatment at baseline were administered placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.

Experimental: BI 1015550, Non-antifibrotics at baseline - Idiopathic pulmonary fibrosis (IPF) patients not on stable antifibrotic treatment at baseline were administered 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.


Treatment: Drugs: BI 1015550
18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.

Treatment: Drugs: Placebo
placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks
Timepoint [1] 0 0
Baseline (day 1) and week 12.
Secondary outcome [1] 0 0
The Number of Patients With Treatment Emergent Adverse Event
Timepoint [1] 0 0
From the start of treatment till the end of treatment + 7 days residual effect period, an average of 87.4 days.

Eligibility
Key inclusion criteria
1. Patients aged =40 years when signing the informed consent.

2. Diagnosis:

1. IPF based on 2018 ATS/ERS/JRS/ALAT Guideline as confirmed by the investigator
based on chest High Resolution Computed Tomography Scan (HRCT) scan taken within
12 months of Visit 1 and if available surgical lung biopsy.

and

2. Usual interstitial pneumonia (UIP) or probable UIP HRCT pattern consistent with
the clinical diagnosis of IPF, as confirmed by central review prior to Visit 2*

- if indeterminate HRCT finding IPF may be confirmed locally by (historical)
biopsy

3. Stable for at least 8 weeks prior to Visit 1. Patients have to be either :

- not on therapy with nintedanib or pirfenidone for at least 8 weeks prior to Visit
1 (combination of nintedanib plus pirfenidone not allowed), or

- on stable* therapy with nintedanib or pirfenidone for at least 8 weeks prior to
Visit 1 and planning to stay stable on this background therapy after
randomisation.

[*stable therapy is defined as the individually and general tolerated regimen of
either pirfenidone or nintedanib]

4. Forced Vital Capacity (FVC) =45% of predicted normal at Visit 1

5. Diffusion capacity of the lung for carbon monoxide (DLCO) (corrected for haemoglobin
[Hb] [Visit 1]) = 25% to < 80% of predicted normal at Visit 1.

6. Signed and dated written informed consent in accordance with ICH-GCP and local
legislation prior to admission to the trial.
Minimum age
40 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Relevant airways obstruction (pre-bronchodilator Forced Expiratory Volume in one
second (FEV1)/Forced Vital Capacity (FVC) < 0.7) at Visit 1.

2. In the opinion of the Investigator, other clinically significant pulmonary
abnormalities.

3. Acute IPF exacerbation within 4 months prior to screening and/or during the screening
period (investigator-determined).

4. Lower respiratory tract infection requiring antibiotics within 4 weeks prior to Visit
1 and/or during the screening period.

5. Major surgery (major according to the investigator's assessment) performed within 3
months prior to Visit 1 or planned during the course of the trial. (Being on a
transplant list is allowed).

6. Any documented active or suspected malignancy or history of malignancy within 5 years
prior to Visit 1, except appropriately treated basal cell carcinoma of the skin,
"under surveillance" prostate cancer or in situ carcinoma of uterine cervix.

7. Evidence of active infection (chronic or acute) based on clinical exam or laboratory
findings at Visit 1 or at Visit 2.

8. Any suicidal behaviour in the past 2 years (i.e. actual attempt, interrupted attempt,
aborted attempt, or preparatory acts or behavior).

9. The patient has a confirmed infection with SARS-CoV-2 within the 4 weeks prior to
Visit 1 and/or during the screening period.

Further exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/07/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
15/10/2021
Sample size
Target
Accrual to date
Final
147
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
The Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
Kansas
Country [3] 0 0
United States of America
State/province [3] 0 0
Minnesota
Country [4] 0 0
United States of America
State/province [4] 0 0
Missouri
Country [5] 0 0
United States of America
State/province [5] 0 0
Nebraska
Country [6] 0 0
United States of America
State/province [6] 0 0
North Carolina
Country [7] 0 0
United States of America
State/province [7] 0 0
Ohio
Country [8] 0 0
United States of America
State/province [8] 0 0
Pennsylvania
Country [9] 0 0
United States of America
State/province [9] 0 0
Texas
Country [10] 0 0
United States of America
State/province [10] 0 0
Utah
Country [11] 0 0
Argentina
State/province [11] 0 0
C.a.b.a
Country [12] 0 0
Austria
State/province [12] 0 0
Graz
Country [13] 0 0
Canada
State/province [13] 0 0
British Columbia
Country [14] 0 0
Canada
State/province [14] 0 0
New Brunswick
Country [15] 0 0
Canada
State/province [15] 0 0
Ontario
Country [16] 0 0
Canada
State/province [16] 0 0
Quebec
Country [17] 0 0
Chile
State/province [17] 0 0
Providencia, Santiago De Chile
Country [18] 0 0
Chile
State/province [18] 0 0
Talca
Country [19] 0 0
China
State/province [19] 0 0
Beijing
Country [20] 0 0
China
State/province [20] 0 0
Changchun
Country [21] 0 0
China
State/province [21] 0 0
Chengdu
Country [22] 0 0
China
State/province [22] 0 0
Shanghai
Country [23] 0 0
Czechia
State/province [23] 0 0
Praha 4 - Krc
Country [24] 0 0
Czechia
State/province [24] 0 0
Praha
Country [25] 0 0
Denmark
State/province [25] 0 0
Aarhus N
Country [26] 0 0
Denmark
State/province [26] 0 0
Hellerup
Country [27] 0 0
Denmark
State/province [27] 0 0
Odense C
Country [28] 0 0
Finland
State/province [28] 0 0
Helsinki
Country [29] 0 0
Finland
State/province [29] 0 0
Kuopio
Country [30] 0 0
Finland
State/province [30] 0 0
Oulu
Country [31] 0 0
Finland
State/province [31] 0 0
Tampere
Country [32] 0 0
Finland
State/province [32] 0 0
Turku
Country [33] 0 0
Germany
State/province [33] 0 0
Coswig
Country [34] 0 0
Germany
State/province [34] 0 0
Essen
Country [35] 0 0
Germany
State/province [35] 0 0
Heidelberg
Country [36] 0 0
Germany
State/province [36] 0 0
Immenhausen
Country [37] 0 0
Germany
State/province [37] 0 0
Münster
Country [38] 0 0
Greece
State/province [38] 0 0
Athens
Country [39] 0 0
Greece
State/province [39] 0 0
Crete
Country [40] 0 0
Greece
State/province [40] 0 0
Patras
Country [41] 0 0
Hungary
State/province [41] 0 0
Budapest
Country [42] 0 0
Italy
State/province [42] 0 0
Foggia
Country [43] 0 0
Italy
State/province [43] 0 0
Padova
Country [44] 0 0
Italy
State/province [44] 0 0
Roma
Country [45] 0 0
Italy
State/province [45] 0 0
Siena
Country [46] 0 0
Japan
State/province [46] 0 0
Aichi, Seto
Country [47] 0 0
Japan
State/province [47] 0 0
Fukuoka, Fukuoka
Country [48] 0 0
Japan
State/province [48] 0 0
Kanagawa, Yokohama
Country [49] 0 0
Japan
State/province [49] 0 0
Osaka, Sakai
Country [50] 0 0
Japan
State/province [50] 0 0
Shizuoka, Hamamatsu
Country [51] 0 0
Japan
State/province [51] 0 0
Tokyo, Shinjuku-ku
Country [52] 0 0
Korea, Republic of
State/province [52] 0 0
Bucheon
Country [53] 0 0
Korea, Republic of
State/province [53] 0 0
Seoul
Country [54] 0 0
Netherlands
State/province [54] 0 0
Heerlen
Country [55] 0 0
Netherlands
State/province [55] 0 0
Nieuwegein
Country [56] 0 0
Netherlands
State/province [56] 0 0
Rotterdam
Country [57] 0 0
Poland
State/province [57] 0 0
Gdansk
Country [58] 0 0
Russian Federation
State/province [58] 0 0
Moscow
Country [59] 0 0
Russian Federation
State/province [59] 0 0
Yaroslavl
Country [60] 0 0
Spain
State/province [60] 0 0
Barcelona
Country [61] 0 0
Spain
State/province [61] 0 0
L'Hospitalet de Llobregat
Country [62] 0 0
Spain
State/province [62] 0 0
Madrid
Country [63] 0 0
Spain
State/province [63] 0 0
Oviedo
Country [64] 0 0
Spain
State/province [64] 0 0
Palma de Mallorca
Country [65] 0 0
Ukraine
State/province [65] 0 0
Dnyepropyetrovsk
Country [66] 0 0
Ukraine
State/province [66] 0 0
Kyiv
Country [67] 0 0
United Kingdom
State/province [67] 0 0
Bristol
Country [68] 0 0
United Kingdom
State/province [68] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are at least 40
years old. People taking standard medicines for IPF, including antifibrotic medicines, can
continue taking them throughout the study.

The purpose of the study is to find out whether a medicine called BI 1015550 can slow down
the worsening of lung function. Participants are in the study for about 4 months. During this
time, they visit the study site about 7 times. At the beginning, they visit the study site
every 2 weeks.

After 1 month of treatment, they visit the study site every 4 weeks.

The participants are put into 2 groups by chance. 1 group gets BI 1015550. The other group
gets placebo. Placebo tablets look like BI 1015550 tablets but contain no medicine. The
participants take BI 1015550 or placebo tablets twice a day.

The participants have lung function tests at study visits. The results of the lung function
tests are compared between the BI 1015550 group and the placebo group. The doctors also
regularly check the general health of the participants.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04419506
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04419506